Endocyte (NASDAQ:ECYT)’s shares saw strong trading volume on Friday after the company announced better than expected quarterly earnings, American Banking and Market News reports. 13,778,961 shares changed hands during trading, an increase of 624% from the previous session’s volume of 1,903,723 shares. Endocyte, Inc. (NASDAQ:ECYT) stock performance was 61.91% in last session and finished the day at $ 6.62. Traded volume was 17,639,435 shares in the last session and the average volume of the stock remained 1,621,530 shares. The beta of the stock remained 1.07. Endocyte, Inc. (NASDAQ:ECYT) insider ownership is 1.40%.

Gilead Sciences (NASDAQ:GILD) had its price target upped by Maxim Group from $101.00 to $112.00 in a research note issued to investors on Monday. The firm currently has a buy rating on the stock. Gilead Sciences, Inc. (NASDAQ:GILD)rose 8.95 percent to $ 16,776,561 yesterday on volume of 77.71 million shares. The intra-day range of the stock was $ 76.65 to 79.50. Gilead Sciences, Inc. (NASDAQ:GILD) has a market capitalization of $ 119.49 billion.

Arena Pharmaceuticals (NASDAQ:ARNA) last announced its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.13. The company had revenue of $6.50 million for the quarter, compared to the consensus estimate of $7.00 million. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s stock on May 2, 2014 reported an increase of 0.30%% to the closing price of $ 6.68. Its fifty two weeks range is $ 4.05 to 9.25. The total market capitalization recorded $109.75 billion. The overall volume in the last trading session was 1.46 billion shares. In its share capital, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has 219.27 million outstanding shares.

Immunomedics, Inc. (NASDAQ:IMMU) announced that it is offering to sell, subject to market and other conditions, shares of its common stock pursuant to an effective shelf registration statement. In connection with this offering, Immunomedics intends to grant the underwriters a 30-day option to purchase additional shares of common stock. On Friday, shares of Immunomedics, Inc. (NASDAQ:IMMU) advanced/dropped 21.98% to close the day at $ 3.23. Company return on investment (ROI) is -40.00% and its monthly performance are recorded as -26.42%. Immunomedics, Inc. (NASDAQ:IMMU) quarterly revenue growth is -33.40%.